Association between Menopausal Hormone Therapy and Behcet’s Disease:A Population-Based Study
- Author:
Soyeon YUN
1
;
Eun Hee YOO
;
Esther KIM
;
Yeong Ho KIM
;
Dong Su YU
;
Ji Hyun LEE
Author Information
1. Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea
- Publication Type:Original Article
- From:Korean Journal of Dermatology
2024;62(7):382-390
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The pathogenesis and development of autoimmune diseases are associated with alteration of hormone levels. The effects of menopausal hormone therapy (MHT) on Behcet’s disease (BD) are unclear.
Objective:We hypothesized that MHT would increase the risk of BD in postmenopausal women due to the central role of immunomodulation of estrogen and other sex hormones in autoimmune diseases.
Methods:We analyzed data from the Korean National Health Insurance Service database and investigated the relationship between MHT and the risk of BD in postmenopausal women with BD. The study included 220,663 patients who received MHT and 1,170,566 who did not. The hazard ratio (HR) of BD was measured in all subjects.Statistical analyses were utilized with adjustments for possible confounding factors such as age, body mass index, smoking, alcohol consumption, physical activity, income, diabetes, hypertension, dyslipidemia, age at menarche (group), age at menopause (group), parity, breastfeeding, and oral contraceptive use.
Results:After adjusting for confounding factors, the participants with a history of MHT had a higher risk of BD (MHT＜2 years, HR=1.459, 95% confidence interval [95% CI]=1.29∼1.649; MHT＞2 and ＜5 years, HR=1.512, 95% CI=1.265∼1.808; MHT≥5 years, HR=2.045, 95% CI=1.708∼2.447).
Conclusion:The findings demonstrate that MHT is associated with an increased risk of BD in postmenopausal women, indicating that estrogen plays an important role in the disease activity of BD. However, additional studies are needed to confirm these findings.
